PAFOS: Study of Factors Associated With the Volumetric and Areal Bone Mineral Density and Bone Strength in Parkinson's Disease

Sponsor
University Hospital, Clermont-Ferrand (Other)
Overall Status
Recruiting
CT.gov ID
NCT02930512
Collaborator
(none)
200
1
72.3
2.8

Study Details

Study Description

Brief Summary

Studies show that patients with idiopathic Parkinson's disease (IPD) have an increased risk of fracture, particularly hip fracture whose complications and postoperative mortality appear to be higher than in the general population.

This increased risk of fracture is due partly to an increased risk of falling, and secondly to an impairment of bone tissue with lower bone mineral density (BMD). A meta-analysis concluded that patients with IPD have lower BMD than healthy controls. Prospective studies also showed rapid bone loss in these patients compared with controls. The association between low BMD and IPD seems dependent on the severity and duration of the disease even if some data are contradictory. Various mechanisms may explain this bone loss including weight loss, malnutrition and a low level of physical activity. However, enrollments in these studies are often weak and it is difficult to conclude on the real impact of these factors on bone loss in the IPD. The main objective of our study is to assess and prioritize from these various bone loss mechanisms. Bone assessment by "peripheral quantitative computed tomography" (pQCT) will also assess the impact of various risk factors on bone strength parameters. The prevalence of vertebral compression fractures in the IPD, at this day unknown can be evaluated. This study will also estimate the prevalence of vertebral compression fractures in the IPD.

Condition or Disease Intervention/Treatment Phase
  • Procedure: DXA scan
  • Procedure: pQCT scan

Detailed Description

Studies show that patients with idiopathic Parkinson's disease (IPD) have an increased risk of fracture, particularly hip fracture whose complications and postoperative mortality appear to be higher than in the general population.

This increased risk of fracture is due partly to an increased risk of falling, and secondly to an impairment of bone tissue with lower bone mineral density (BMD). A meta-analysis concluded that patients with IPD have lower BMD than healthy controls. Prospective studies also showed rapid bone loss in these patients compared with controls. The association between low BMD and IPD seems dependent on the severity and duration of the disease even if some data are contradictory. Various mechanisms may explain this bone loss including weight loss, malnutrition and a low level of physical activity. However, enrollments in these studies are often weak and it is difficult to conclude on the real impact of these factors on bone loss in the IPD. The main objective of our study is to assess and prioritize from these various bone loss mechanisms. Bone assessment by "peripheral quantitative computed tomography" (pQCT) will also assess the impact of various risk factors on bone strength parameters. The prevalence of vertebral compression fractures in the IPD, at this day unknown can be evaluated. This study will also estimate the prevalence of vertebral compression fractures in the IPD.

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Other
Time Perspective:
Cross-Sectional
Official Title:
Study of Factors Associated With the Volumetric and Areal Bone Mineral Density and Bone Strength in Parkinson's Disease
Actual Study Start Date :
Jun 21, 2016
Anticipated Primary Completion Date :
Jul 1, 2022
Anticipated Study Completion Date :
Jul 1, 2022

Arms and Interventions

Arm Intervention/Treatment
patients with idiopathic Parkinson's disease

Procedure: DXA scan

Procedure: pQCT scan

Outcome Measures

Primary Outcome Measures

  1. Total bone mineral density of the tibia and radius quantified by peripheral quantitative computed tomography (pQCT) [at day 1]

Secondary Outcome Measures

  1. Trabecular and cortical bone mineral density of the tibia and the radius [at day 1]

  2. Architectural parameters and bone resistance of the tibia and radius measured by pQCT [at day 1]

  3. Axial muscular area of the tibia and radius measured by pQCT [at day 1]

  4. Bone mineral density of the lumbar spine and hip measured by DXA [at day 1]

  5. body composition by DXA [at day 1]

  6. Parkinson's disease score [at day 1]

  7. Bone turnovers markers (CTX), 25 OH vitamin D [at day 1]

  8. Vertebral fracture assessment (VFA) [at day 1]

  9. Trabecular bone score of the lumbar spine [at day 1]

Eligibility Criteria

Criteria

Ages Eligible for Study:
35 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Idiopathic parkinson's disease (UKPDSBB criteria)

  • Hoen and Yahr score < 4 (ON periods)

  • Age between 35 and 70 years old

  • Independent person at home

Exclusion Criteria:
  • Dementia patient and progressive mental illness

  • Patient with severe tremor

  • Incapacity to walk over ten minutes

  • Treatment influencing bone metabolism

  • Disease influencing phosphocalcic metabolism

  • Severe comorbidities

  • Pregnant woman

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU Clermont-Ferrand Clermont-Ferrand France 63003

Sponsors and Collaborators

  • University Hospital, Clermont-Ferrand

Investigators

  • Principal Investigator: Sandrine MALOCHET, University Hospital, Clermont-Ferrand

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier:
NCT02930512
Other Study ID Numbers:
  • CHU-0281
  • 2016-A00458-43
First Posted:
Oct 12, 2016
Last Update Posted:
Feb 16, 2021
Last Verified:
Feb 1, 2021
Keywords provided by University Hospital, Clermont-Ferrand
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 16, 2021